Obbligazione Barclay PLC 0.604% ( US06740PC389 ) in USD

Barclay PLC

74.5 USD ▲

Regno Unito

US06740PC389 ( in USD )

0.604% per anno ( pagato 2 volte l'anno)

29/11/2030

Prospetto opuscolo dell'obbligazione Barclays PLC US06740PC389 en USD 0.604%, scadenza 29/11/2030

1 000 USD

1 000 000 USD

06740PC38

N/A

29/05/2025 ( In 5 giorni )

Barclays PLC è una banca multinazionale britannica che offre una vasta gamma di servizi finanziari a clienti privati, aziende e istituzioni in tutto il mondo.

The Obbligazione issued by Barclay PLC ( United Kingdom ) , in USD, with the ISIN code US06740PC389, pays a coupon of 0.604% per year.
The coupons are paid 2 times per year and the Obbligazione maturity is 29/11/2030

The Obbligazione issued by Barclay PLC ( United Kingdom ) , in USD, with the ISIN code US06740PC389, was rated NR by Moody's credit rating agency.

Pricing Supplement - 20ync1y Steepener
Page 1 of 12
424B2 1 d424b2.htm PRICING SUPPLEMENT - 20YNC1Y STEEPENER

CALCULATION OF REGISTRATION FEE

Title of Each Class of Securities Offered

Maximum Aggregate Offering Price
Amount of Registration Fee(1)
Global Medium-Term Notes, Series A

$1,000,000
$71.30
(1) Calculated in accordance with Rule 457(r) of the Securities Act of 1933.
http://sec.gov/Archives/edgar/data/312070/000119312510238340/d424b2.htm
10/28/2010

Pricing Supplement - 20ync1y Steepener
Page 2 of 12

Pricing Supplement dated October 28, 2010
Filed Pursuant to Rule 424(b)(2)
(To Prospectus dated August 31, 2010 and
Registration No. 333-169119
the Prospectus Supplement dated August 31, 2010)

U
C
P
Itf
dC
0B
IR
1F
4pa S
r
U
Se
Gli
h
O
N
U
Derc
M
IS
niniI
u
a

M0
Mo0
a $1
A
ssue
rai
UI
Mre
a
N
M
Py
3r
Fi
R
0
Ms
you:
Eux
e
0
S
xed
itial 00
ssuer:
Barclays
P:
obal
bir
C
00%
25% ri
Variable
rectly
iginal
tober
Maturity
SIP:
New
o
Othe
terest
00%
SPI
00%
terest
eac
terestrdh
yable 0
incipal
00
M
incipalor
lity
ovember
2
ovember
nimum
sinessY
Londo
siness
ou
nverse
Otherei (
30/360
/365
ference
ximum
pre
nimum
per
rI
ference
Multiplier
November
n
pplicable 000
LLABLE
A
ce:
P
hold7
n
D
Followi
nt
R
gular
peraI
per
Multiplier:
For Interest
onthlyt
in
of
29
6740PC38
Denominatio
da
odifiedFI
Ry
ng
eceding
Adjusted
Rate
at
see
Aa
d:
Rate
nteP
29
r C
000
Bank
Price
he
Issue
Trade
Date:
Day:
orkoerr
Actual/360
Actual/365
NL/365
Actual/366
Actual/252
nterestr
ate
e MS
mount:
R
ediumD
ns:
06740PC389
C
d
Actual/Actua
r e
rotectio
D
2010

Type
Conv
loating
l
or
nterest
nnum
CMS
nterest
nnum
centage
nnum
est
Payment P
sD
Qu
earsa STEEPE
PLCO
n
Barcla
ate:
2010
2030
onv(
Floating
ate:e
iods
2011r
o ffer
Term
directly
RP
Notes
ate:
enominats
R
sset/Ref
Rr
ubjc
te
n erce
t
ys
R
Formula:o
an
Following
ee
ention
ate
escripti
ate:
iod
ect
o
ates:
rl m
Bank
sub(
ate:y
hej
ions
ate
on
ate ect
Unadju
In(cof
ention:
orin
Business
erence
w
Amount:o
to N
Notes
atu
see
D r
steda
ith
the
29th ER
S
ntage:
ity
obligat
PLC
to
terest
Frac
pao R
this
Rate:m
M
mmencing
Semi
f eNO
eries
iont
US$1a
ageo o
ote
S
ys/252n
A fs
tion):
mmencing
achTES
A
you
Redem4
o will
a
a
000orny
p
Fo1
pricing of
s
aturityn
inimuma o
f
MatyD
tisfy
andr
tion
ofr i
nnuallyaU
it
er:s
at
n
rmula
thefE
third
10ttibp
er
Intere
nd N
eceive
p
he
st
A O
ntegr
upplementV
at
arty
obligaa)
years
the l
elow):
Nov
RateEMBER
lea
m
Oe
Novembs
m
nnually t
and
tions
Optionul
rospectus
and
er a
o
inus
rigintny
asfa
mber tl
heI
29 2
100%
he
tiples 9
theyo
CMS f 2030
of
Co
suppleme
R
ssue your
payment
come
Un
commen t
ate
D
2011c f t
S$1
w
ate
Maximum
ing principal
o
mpany
orit
theIob
due
i(
ah
on e
000
da m
as
but
M ae
ntere d
setx
st
nterest
ay efrs
R
29u
o b
n
maturity
ate ject
orth
thereafte
escriptiontrhe
o
p f
of
cluding
er i2
2011 to
y the
Notes
below)
ea
and rs
annum
e c
nverse iredit
f
min
November u
will
nding w
nclud
s
29i
beorthiness
ng
loating
t
on r
he
eq
than
2011
e y
ate:
ual t
M p
N
Fixed
he
to o
P
t
aturf
rinc
heB
otes)
ity arclays
ipal
Initial pr
ercentaI
Da ge
product
te or B
ntere
ofank
otection
Am
st(R
1)
the E P
p LC
ount
ate
the M
arly The
rovided
ultipN
at otes
m
lier a
Redemption are
aturity
ndD n
(2)
ateo
dtteif e
he ither
pends on
http://sec.gov/Archives/edgar/data/312070/000119312510238340/d424b2.htm
10/28/2010

Pricing Supplement - 20ync1y Steepener
Page 3 of 12

Itn
T
w
IF
R
pecr
Rf
bS
D
L
T
C
B
5r
T
b terest
h
oe
xuiae
illr
w
Wet
T
We f
o
weei
C;
Notes
ing r
be
terest
eac
terest
N
ma
xc
sting:
No
00%t
ma
marketu Period:
sth
ey
ovided
erciset
rclaysr
o
iminaly Inte
gin
BoI
wr
es
ep
esu o
demption
w
sed e
will
demption
exerci
ttlement:
ok
lculation
ansactions
ay
mmission
sei rest
n
Reset
ntera
edeeg
P
se
ludinge
A
resalen a
PeriodD
est
York
tn
will
Bank t
m
be
Capital
sulting
or
has
offense
this Pe
nd
will
ive
theP
Determina
hey
ourIi
a o
a
ref
rice:E
try;
not
gent:n
not riod
incl
te
ates:
e
PLCru
ea
nc
selling n
Opr
l
be
otherc
be d
iod
tion
BusineN
rred
ly
gg
w
pricing
market w
ude
oc
D
east
redem
hasa
ss
tiontp
ise
pproveds
transaction ill
notfae:
o
ote
Re
listedf
sa
a
otr
in begi
the
but
Days
resalet
ives
tion
Transferab
o
regate tn
vd I
he
inhe
o
le
oncession p
a
greeds
any n
exc"
ny
to
o
nyol
who
demption
r
N n
nterest
mmencing
priorl
E
tion
aryingf
upplement te
business
aD
U
proceeds
i a
udeoS
ees
n
otes n
Pntr
d
rlya
transaction do
h
o
isapprovede
Companyi
R
you
ateto
he
f inclu
ayment
ther:
n
ays
B
prices
ofiM
a'
purchase
ter f
pt
n t
rele
art
p
to r
willhr
he
otheed
er
be
r
itiale
vant
a
iord
hese
ir t
securities
arclays
securitiess t
e
eahe
Date
aturity
Nov
I
w
edemption
B
se
ini e
n
he
eceive
Notes
deter
ale Original
for
Df
ank
m
lers
o
tial t
Re
ritten
ons he
Date
mber
terest
ate"
th
xchange
rom
P
ined
xchange
curities
Nale p
(or
eu
LCo rt
29E
ors
at
or
otesU Issue
he
Reset
noticea
ofdIt
artenEa
2011
D
demption
o
ly
thet P
t
nless D
eceding
rly
ate
he
100%
$950
addit
w ate
I
timeeR
the
rice
Rede
quotationi e
ofs
of
000
ermined
on
or a
d
settnd
nterest
irstf
trustee
the
hat
our end
P
day
orth
I
mptionp
eachf
ystem
Barc
ystemtDb
w
rinc
N
his o
emption
ofe
lays
salep
Barclays
agentn
eriodD
atese1
ipal
i but
and
ate
uch
low
Ca
either o
xerc
am
ricing exclude
end
iIfn
00%
pital
the
Capital a
iseo
nforms f
I
BarclaysS
I o
nter
ount
ncen
est
ny
our
the
m
c
nc
you P
Inp
ior the
but
pplicab
er
nus
Capital eI
urities
supplement f
le)
terest
ai i
x
iodas r
rincipc
proposes
nc st
al
nd
t
another
otherwise Inte
clude
redemption
to
mEoio
amo
ommi
ay
xf
n t rest
the
Payment
ffer
a
ruthful o
our
he n
D
ption
unt
ssion
t
lsor Pa
t
heu
change
co
confyment
ext
atesefc
he
together
equ
mal
Not
allt
e
affiliateso
s r
plete D
ma
irmation ate
ollowing
ommenci
Interest
with
$50
from
A
ayofn
Commission
nysE
g
per
use ach
Inter
o
any
time
nor
t
ale e
n
Paymen
$1
portionto
hist subseque
st
Ntf Paym
ovembe
D
any
represe
p
his ate
accrued
000
time
itss
n
rip o
af
tate
cing n
or
com
tation nt
entr
ndw
princip
mt
ricingo
sups Inte
Da
sal a
29le
p te
hich
ain
the
le r
20
issioncest
T
unpaid
mo
s
securities h
11
weo
ment P
e
int
unt
n
ontr
upplemene
fai
so
negott
in r
hiiod
n
o
rya
erestr
es l
iatet
iso
da
http://sec.gov/Archives/edgar/data/312070/000119312510238340/d424b2.htm
10/28/2010

Pricing Supplement - 20ync1y Steepener
Page 4 of 12

The Notes constitute our direct, unconditional, unsecured and unsubordinated obligations and are not deposit
liabilities of Barclays Bank PLC and are not insured by the U.S. Federal Deposit Insurance Corporation or any other
governmental agency of the United States, the United Kingdom or any other jurisdiction.
Investing in the Notes involves a number of risks. See "Risk Factors" beginning on page S-5 of the prospectus
supplement and "Selected Risk Factors" below. We urge you to consult your investment, legal, tax, accounting and
other advisers and to invest in the Notes only after you and your advisors have carefully considered the suitability of
an investment in the Notes in light of your particular circumstances.
Barclays Bank PLC has filed a registration statement (including a prospectus) with the SEC for the offering to which
this pricing supplement relates. Before you invest, you should read the prospectus dated August 31, 2010, the
prospectus supplement dated August 31, 2010, and other documents Barclays Bank PLC has filed with the SEC for
more complete information about Barclays Bank PLC and this offering. Buyers should rely upon this pricing
supplement, the prospectus, the prospectus supplement, and any relevant free writing prospectus for complete details.
You may get these documents and other documents Barclays Bank PLC has filed for free by visiting EDGAR on the
SEC website at www.sec.gov, and you may also access the prospectus and prospectus supplement through the links
below:

·
Prospectus dated August 31, 2010:
http://www.sec.gov/Archives/edgar/data/312070/000119312510201448/df3asr.htm

·
Prospectus Supplement dated August 31, 2010:
http://www.sec.gov/Archives/edgar/data/312070/000119312510201604/d424b3.htm
Our Central Index Key, or CIK, on the SEC website is 1-10257.
Alternatively, Barclays Capital Inc. or any agent or dealer participating in this offering will arrange to send you this
pricing supplement, the prospectus, the prospectus supplement and any relevant free writing prospectus if you
request it by calling your Barclays Capital Inc. sales representative, such dealer or 1-888-227-2275 (Extension 2-3430).
A copy of the prospectus may be obtained from Barclays Capital Inc., 745 Seventh Avenue--Attn: US InvSol
Support, New York, NY 10019.
You may revoke your offer to purchase the Notes at any time prior to the time at which we accept such offer by notifying the
applicable agent. We reserve the right to change the terms of, or reject any offer to purchase the Notes prior to their issuance.
In the event of any changes to the terms of the Notes, we will notify you and you will be asked to accept such changes in
connection with your purchase. You may also choose to reject such changes in which case we may reject your offer to
purchase.
As used in this term sheet, the "Company," "we," "us," or "our" refers to Barclays Bank PLC.
http://sec.gov/Archives/edgar/data/312070/000119312510238340/d424b2.htm
10/28/2010

Pricing Supplement - 20ync1y Steepener
Page 5 of 12

SELECTED RISK FACTORS
An investment in the Notes involves significant risks not associated with an investment in conventional floating rate or
fixed rate medium term notes. You should read the risks summarized below in connection with, and the risks
summarized below are qualified by reference to, the risks described in more detail in the "Risk Factors" section
beginning on page S-5 of the prospectus supplement. We urge you to consult your investment, legal, tax, accounting
and other advisers and to invest in the Notes only after you and your advisors have carefully considered the suitability
of an investment in the Notes in light of your particular circumstances.

·
Reference Rate / Interest Payment Risk--Investing in the Notes is not equivalent to investing in securities
directly linked to the relevant CMS Rates or the Reference Rate. Instead, the amount of interest payable on the
Notes (after the initial Interest Periods for which the Initial Interest Rate is payable) is determined by multiplying
the (a) Multiplier by (b) the difference between the CMS Rates of the two maturities identified on the cover page
hereof minus the Fixed Percentage Amount (the Reference Rate, or "CMS Spread"), as determined on the Interest
Determination Date applicable to the relevant Interest Period, subject to the Minimum Interest Rate and the
Maximum Interest Rate. Accordingly, the amount of interest payable on the Notes is dependent on whether, and the
extent to which, the CMS Spread is greater than zero on the Interest Determination Date. As the interest payments

on the Notes are subject to the Minimum Interest Rate of 0%, if the CMS Spread on any Interest Determination
Date is equal to or less than zero, you would receive no interest payment on the related Interest Payment Date. If
the CMS Spread is equal to or less than zero on every Interest Determination Date throughout the term of the
Notes, then you would receive no interest payments on your Notes throughout their term. Moreover, interest
payments on the Notes are subject to the Maximum Interest Rate (as specified on the cover page hereof). As a
result, you will not benefit in any increase in the CMS Spread that results in a per annum interest rate (when such
CMS Spread is multiplied by the Multiplier) that is greater than the specified Maximum Interest Rate, and the yield
on such Notes may be less than the yield on a similar security based on the Reference Rate that is not subject to a
Maximum Interest Rate.

·
Issuer Credit Risk--The Notes are our unsecured debt obligations, and are not, either directly or indirectly, an
obligation of any third party. Any payment to be made on the Notes, including any principal protection provided at
maturity, depends on our ability to satisfy our obligations as they come due. As a result, the actual and perceived

creditworthiness of Barclays Bank PLC may affect the market value of the Notes and, in the event we were to
default on our obligations, you may not receive the principal protection or any other amounts owed to you under
the terms of the Notes.

·
Certain Built-In Costs Are Likely to Adversely Affect the Value of the Notes Prior to Maturity--Although
you will not receive less than the principal amount of the Notes if you hold the Notes to maturity (subject to Issuer
credit risk), the Original Issue Price of the Notes includes the Agent's commission and the cost of hedging our

obligations under the Notes through one or more of our affiliates. As a result, assuming no change in market
conditions or any other relevant factor, the price, if any, at which Barclays Capital Inc. and other affiliates of
Barclays Bank PLC will be willing to purchase Notes from you in secondary market transactions will likely be
lower than the Original Issue Price, and any sale prior to the Maturity Date could result in a substantial loss to you.

·
Lack of Liquidity--The Notes will not be listed on any securities exchange. Barclays Capital Inc. and other
affiliates of Barclays Bank PLC intend to make a secondary market for the Notes but are not required to do so, and
may discontinue any such secondary market making at any time, without notice. Even if there is a secondary
market, it may not provide enough liquidity to allow you to trade or sell the Notes easily. Because other dealers are

not likely to make a secondary market for the Notes, the price at which you may be able to trade your Notes is
likely to depend on the price, if any, at which Barclays Capital Inc. and other affiliates of Barclays Bank PLC are
willing to buy the Notes. The Notes are not designed to be short-term trading instruments. Accordingly, you should
be able and willing to hold your Notes to maturity.

·
Potential Conflicts--We and our affiliates play a variety of roles in connection with the issuance of the Notes,
including acting as calculation agent and hedging our obligations under the Notes. In performing these duties, the

economic interests of the calculation agent and other affiliates of ours are potentially adverse to your interests as an
investor in the Notes.

PS1
http://sec.gov/Archives/edgar/data/312070/000119312510238340/d424b2.htm
10/28/2010

Pricing Supplement - 20ync1y Steepener
Page 6 of 12

In addition, Barclays Wealth, the wealth management division of Barclays Capital Inc., may arrange for the sale of
the Notes to certain of its clients. In doing so, Barclays Wealth will be acting as agent for Barclays Bank PLC and
may receive compensation from Barclays Bank PLC in the form of discounts and commissions. The role of
Barclays Wealth as a provider of certain services to such customers and as agent for Barclays Bank PLC in
connection with the distribution of the Notes to investors may create a potential conflict of interest, which may be
adverse to such clients. Barclays Wealth is not acting as your agent or investment adviser, and is not representing
you in any capacity with respect to any purchase of Notes by you. Barclays Wealth is acting solely as agent for
Barclays Bank PLC. If you are considering whether to invest in the Notes through Barclays Wealth, we strongly
urge you to seek independent financial and investment advice to assess the merits of such investment.

·
Many Economic and Market Factors Will Impact the Value of the Notes--In addition to the level of the

Reference Rate on any day, the value of the Notes will be affected by a number of economic and market factors
that may either offset or magnify each other, including:

·
the expected volatility of the Reference Rate;

·
the time to maturity of the Notes;

·
interest and yield rates in the market generally;

·
a variety of economic, financial, political, regulatory or judicial events; and

·
our creditworthiness, including actual or anticipated downgrades in our credit ratings.
HYPOTHETICAL INTEREST RATE AND INTEREST PAYMENT CALCULATIONS
As described above, after the initial Interest Periods for which the Initial Interest Rate is payable, the Notes will pay interest
on each Interest Payment Date at a per annum interest rate calculated in accordance with the Interest Rate Formula. The
following illustrates the process by which the interest rate and interest payment amount are determined for any such Interest
Periods.
For purposes of these examples, we assume that the Notes are not being redeemed on the applicable Interest Payment Date
pursuant to the Redemption at the Option of the Company provisions above. If we exercise our redemption option, you will
receive on the Early Redemption Date the Early Redemption Price applicable to that Early Redemption Date, calculated as
described above.
Interest Rate Calculation
Step 1: Calculate the Reference Rate.
For each Interest Period, a value for the Reference Rate is determined by calculating the CMS Spread, which is the difference
between the CMS Rates of the two maturities identified on the cover page hereof on the Interest Determination Date for that
Interest Period (that is, two New York Business Days prior to the first day of the Interest Period) minus the Fixed Percentage
Amount. If the value of the first CMS Rate is not sufficiently greater than the second CMS Rate, the subtraction of the second
CMS Rate from the first CMS Rate minus the Fixed Percentage Amount will result in a negative CMS Spread, and therefore
a negative Reference Rate.
Step 2: Calculate the per annum interest rate for each Interest Payment Date.
For each Interest Period, the per annum interest rate is determined by multiplying the Multiplier by the Reference Rate,
determined on the Interest Determination Date applicable to the relevant Interest Period as described above, subject to the
Minimum Interest Rate and the Maximum Interest Rate. Although the product of the Multiplier and the Reference Rate could
be a negative number (as described above), with the Minimum Interest Rate equal to 0%, if the Reference Rate on any
Interest Determination Date is equal to or less than zero, the per annum interest rate for that Interest Period would be 0% and
you would receive no interest payment on the related Interest Payment Date. See "Selected Risk Factors--Reference Rate /
Interest Payment Risk". The per annum interest rate will also be limited to the Maximum Interest Rate specified on the cover
page hereof.
Step 3: Calculate the interest payment amount payable for each Interest Payment Date.
For each Interest Period, once the Calculation Agent has determined the applicable interest rate per annum, the Calculation
Agent will calculate the effective interest rate for the Interest Period by multiplying the annual interest rate determined for
that Interest Period by the applicable day count fraction. The resulting effective interest rate is then multiplied by the relevant
principal amount of the Notes to determine the actual interest amount payable on the related Interest Payment Date. No
http://sec.gov/Archives/edgar/data/312070/000119312510238340/d424b2.htm
10/28/2010

Pricing Supplement - 20ync1y Steepener
Page 7 of 12
adjustments to the amount of interest calculated will be made in the event an Interest Payment Date is not a Business Day.

PS2
http://sec.gov/Archives/edgar/data/312070/000119312510238340/d424b2.htm
10/28/2010

Pricing Supplement - 20ync1y Steepener
Page 8 of 12

Example Interest Rate and Interest Payment Calculations
The following examples illustrate how the per annum interest rate and interest payment amounts would be calculated for a
given Interest Period to which the Interest Rate Formula applies under scenarios for the relevant CMS Rates and the
Reference Rate. As set forth on the cover of this pricing supplement, the applicable CMS Spread for the Notes is the
difference of the 10 Year CMS Rate minus the 2 Year CMS Rate minus the Fixed Percentage Amount of 0.25%, the
Multiplier is 4.0, the Minimum Interest Rate is 0.00% and the Maximum Interest Rate is 10.00%. The Notes have semi-
annual Interest Payment Dates, and that interest payments will be calculated using a 30/360 day count basis (such that the
applicable day count fraction for the semi-annual interest payment for the Interest Period will be 180/360).
These values of the 10 year CMS Rate and the 2year CMS Rate in the table below have been chosen arbitrarily for the
purpose of these examples, and should not be taken as indicative of the future performance of the relevant CMS Rates or the
Reference Rate. Numbers in the table below have been rounded for ease of analysis.

Interest Payment
Interest Rate
Effective
Amount
10 Year CMS Rate

2 Year CMS Rate
Reference Rate1
(per annum)2
Interest Rate5

(per $1,000 Note) 6
3.00%

4.20%

1.45%
0.00%3
0.00%

$0.00
5.00%

5.00%

-0.25%
0.00%3
0.00%

$0.00
5.00%

4.75%

0.00%
0.00%
0.00%

$0.00
6.00%

5.30%

0.45%
1.80%
0.90%

$9.00
6.00%

5.10%

0.65%
2.60%
1.30%

$13.00
8.00%

5.00%

2.75%
10.00%4
5.00%

$50.00
1.
For the Interest Period, the value of the Reference Rate is equal to the CMS Spread (the 10 Year CMS Rate minus the 2
Year CMS Rate minus the Fixed Percentage Amount of 0.25%), as determined on the related Interest Determination
Date.
2.
The interest rate per annum is equal to the product of the Multiplier (4.0) and the Reference Rate for that Interest Period,
subject to the Minimum Interest Rate (0.00%) and the Maximum Interest Rate (10.00%).
3.
The interest rate per annum for any Interest Period shall not be less than the Minimum Interest Rate of 0.00%.
4.
The interest rate per annum for any Interest Period shall not be greater than the Maximum Interest Rate of 10.00%.
5.
The effective interest rate for any Interest Period equals the applicable interest rate per annum multiplied by the day
count fraction (180/360).
6.
The interest payment amount for an Interest Payment Date equals the principal amount times the effective interest rate
for the related Interest Period.
Example 1: If on the Interest Determination Date for the relevant Interest Period the value of the 10 Year CMS Rate is 6.00%
and the 2 Year CMS Rate is 5.30%, the Reference Rate for the Interest Period would be 0.45% (equal to the 10 Year CMS
Rate minus the 2 Year CMS Rate minus the Fixed Percentage Amount of 0.25%). In this case, the per annum interest rate for
that Interest Period would be 1.80% (equal to the Reference Rate times the Multiplier of 4.0), and you would receive an
interest payment of $9.00 per $1,000 principal amount of Notes on the related Interest Payment Date, calculated as follows:
Effective Interest Rate = 1.80% × (180/360) = 0.90%
Interest Payment = $1,000 × 0.90% = $9.00
Example 2: If on the Interest Determination Date for the relevant Interest Period the value of the 10 Year CMS Rate is 3.00%
and the 2 Year CMS Rate is 4.20%, the Reference Rate for the Interest Period would be 1.45% (equal to the 10 Year CMS
Rate minus the 2 Year CMS Rate minus the Fixed Percentage Amount of 0.25%). Because the value of the Reference Rate
times the Multiplier of 4.0 results in a per annum interest rate of 5.80%, which is less that Minimum Interest Rate of 0.00%,
the per annum interest rate for that Interest Period would be 0.00% (the Minimum Interest Rate), and you would receive no
interest payment on the related Interest Payment Date (the interest payment would be $0).
Example 3: If on the Interest Determination Date for the relevant Interest Period the value of the 10 Year CMS Rate is 8.00%
and the 2 Year CMS Rate is 5.00%, the Reference Rate for the Interest Period would be 2.75% (equal to the 10 Year CMS
Rate minus the 2 Year CMS Rate minus the Fixed Percentage Amount of 0.25%). Because the value of the Reference Rate
times the Multiplier of 4.0 results in a per annum interest rate of 11.00%, which is greater than the

PS3
http://sec.gov/Archives/edgar/data/312070/000119312510238340/d424b2.htm
10/28/2010

Pricing Supplement - 20ync1y Steepener
Page 9 of 12
Maximum Interest Rate of 10.00%, the per annum interest rate for that Interest Period would be equal to the Maximum
Interest Rate of 10.00%, and you would receive an interest payment of $50.00 per $1,000 principal amount of Notes on the
related Interest Payment Date, calculated as follows:
Effective Interest Rate = 10.00% × (180/360) =5.00%
Interest Payment = $1,000 × 5.00% = $50.00
HISTORICAL INFORMATION
The following table shows for illustrative purposes the 10 Year CMS Rate and the 2 Year CMS Rate in effect on the
hypothetical historical Interest Determination Dates listed below; the Interest Rate payable on any Interest Payment Date for
the Notes, however, will be determined based on the 10 Year CMS Rate and the 2 Year CMS Rate in effect on the Interest
Determination Date for the related Interest Period. The historical experience of the 10 Year CMS Rate and the 2 Year CMS
Rate should not be taken as an indication of the future performance of such rates during the term of the Notes. Fluctuations in
the level of the 10 Year CMS Rate and the 2 Year CMS Rate make the Notes' effective Interest Rate difficult to predict and
can result in effective Interest Rates to investors that are lower than anticipated. In addition, historical interest rates are not
necessarily indicative of future interest rates. Fluctuations in interest rates and interest rate trends that have occurred in the
past are not necessarily indicative of fluctuations that may occur in the future, which may be wider or narrower than those
that have occurred historically.

Hypothetical Interest Reset
Hypothetical Interest Determination
Dates

Dates
10YCMS (%)

2YCMS (%)
5/28/2010

5/26/2010
3.318

1.274
11/30/2009

11/27/2009
3.332

1.038
5/28/2009

5/26/2009
3.603

1.295
11/28/2008

11/26/2008
3.215

2.127
5/28/2008

5/25/2008
3.225

1.267
11/28/2007

11/26/2007
4.728

4.026
5/29/2007

5/25/2007
5.413

5.273
11/28/2006

11/24/2006
5.021

5.044
5/30/2006

5/26/2006
5.593

5.379
11/28/2005

11/24/2005
4.980

4.759
UNITED STATES FEDERAL INCOME TAX TREATMENT
The following discussion (in conjunction with the discussion in the prospectus supplement) summarizes certain of the
material U.S. federal income tax consequences of the purchase, beneficial ownership, and disposition of Notes. This
summary supplements the section "Certain U.S. Federal Income Tax Considerations" in the prospectus supplement and
supersedes it to the extent inconsistent therewith.
We intend to treat the Notes as contingent payment debt instruments subject to taxation as described under the heading
"Certain U.S. Federal Income Tax Considerations--U.S. Federal Income Tax Treatment of the Notes as Indebtedness for
U.S. Federal Income Tax Purposes--Contingent Payment Debt Instruments" in the prospectus supplement. Pursuant to the
terms of the Notes, you agree to treat the Notes consistent with our treatment for all U.S. federal income tax purposes. As a
result, you may be required to include original issue discount ("OID") in income during your ownership of the Notes in
excess of any cash payments made with respect to the Notes in such taxable year. We intend to treat the excess of any non-
contingent payments on the Notes (i.e., the initial 10.00% interest rate) in an accrual period over the product of the
comparable yield of the Notes and their adjusted issue price as a nontaxable return of principal which, in turn, will reduce the
"adjusted issue price" of the Notes. Additionally, you will generally be required to recognize ordinary income on the gain, if
any, realized on a sale, upon maturity, or other disposition of the Notes. Pursuant to the terms of the Notes, you agree to treat
the Notes consistent with our treatment for all U.S. federal income tax purposes.
Because there are no statutory provisions, regulations, published rulings or judicial decisions addressing the characterization
for U.S. federal income tax purposes of securities with terms that are substantially the same as those of the Notes, other
characterizations and treatments are possible. As a result, the timing and character of income in respect of the Notes might
differ from the treatment described above.

PS4
http://sec.gov/Archives/edgar/data/312070/000119312510238340/d424b2.htm
10/28/2010

Pricing Supplement - 20ync1y Steepener
Page 10 of 12
Because Barclays Capital Inc. proposes to offer the Notes at varying prices, the "issue price" of the Notes for federal income
tax purposes may differ from the amount you pay for your Notes. You may obtain the issue price of each Note by contacting
Structuring, Investor Solutions Americas at (212) 412-1101. If you purchase the Notes for an amount that differs from their
issue price, you may be subject to special tax rules as described in "Certain U.S. Federal Income Tax Considerations--U.S.
Federal Income Tax Treatment of the Notes as Indebtedness for U.S. Federal Income Tax Purposes--Contingent Payment
Debt Instruments" in the accompanying prospectus supplement (in particular, the rules that apply when a U.S. holder
purchases a contingent payment debt instrument for an amount that differs from the adjusted issue price of that contingent
payment debt instrument at the time of the purchase). You should consult your own tax advisor regarding these rules.
3.8% Medicare Tax On "Net Investment Income"
Beginning in 2013, U.S. holders that are individuals, estates, and certain trusts will be subject to an additional 3.8% tax on all
or a portion of their "net investment income," which may include the interest payments and any gain realized with respect to
the Notes, to the extent of their net investment income that when added to their other modified adjusted gross income,
exceeds $200,000 for an unmarried individual, $250,000 for a married taxpayer filing a joint return (or a surviving spouse),
or $125,000 for a married individual filing a separate return. U.S. holders should consult their advisors with respect to their
consequences with respect to the 3.8% Medicare tax.
Information Reporting
Holders that are individuals (and, to the extent provided in future regulations, entities) may be subject to certain foreign
financial asset reporting obligations with respect to their Notes if the aggregate value of their Notes and their other "specified
foreign financial assets" exceeds $50,000. Significant penalties can apply if a holder fails to disclose its specified foreign
financial assets. This information reporting requirement is generally applicable for taxable years beginning after March 18,
2010. We urge you to consult your tax advisor with respect to this and other reporting obligations with respect to your Notes.
PROSPECTIVE PURCHASERS SHOULD CONSULT THEIR TAX ADVISORS AS TO THE FEDERAL, STATE,
LOCAL, AND OTHER TAX CONSEQUENCES TO THEM OF THE PURCHASE, OWNERSHIP AND DISPOSITION
OF NOTES.
CERTAIN EMPLOYEE RETIREMENT INCOME SECURITY ACT CONSIDERATIONS
Your purchase of a Note in an Individual Retirement Account (an "IRA"), will be deemed to be a representation and
warranty by you, as a fiduciary of the IRA and also on behalf of the IRA, that (i) neither the issuer, the placement agent nor
any of their respective affiliates has or exercises any discretionary authority or control or acts in a fiduciary capacity with
respect to the IRA assets used to purchase the Note or renders investment advice (within the meaning of Section 3(21)(A)(ii)
of the Employee Retirement Income Security Act ("ERISA")) with respect to any such IRA assets and (ii) in connection with
the purchase of the Note, the IRA will pay no more than "adequate consideration" (within the meaning of Section 408(b)(17)
of ERISA) and in connection with any redemption of the Note pursuant to its terms will receive at least adequate
consideration, and, in making the foregoing representations and warranties, you have (x) applied sound business principles in
determining whether fair market value will be paid, and (y) made such determination acting in good faith.
For additional ERISA considerations, see "Employee Retirement Income Security Act" in the prospectus supplement.

PS5
http://sec.gov/Archives/edgar/data/312070/000119312510238340/d424b2.htm
10/28/2010